RFA
SPHS

Reilly Financial Advisors’s Sophiris Bio, Inc. SPHS Stock Holding History

Reilly Financial Advisors’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-28
Closed – – 1528
2015
Q3 		$0 Hold
28
– – ﹤0.01% 1495
2015
Q2 		$0 Hold
28
– – ﹤0.01% 1523
2015
Q1 		$0 Buy
+28
New +$15 ﹤0.01% 1439

Other funds holding SPHS

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LWAC
Laurel Wealth Advisors (California) Solana Beach, California $1.01B AUM 13.55% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.54% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Reilly Financial Advisors's SPHS Position: Q4 2015 in Review

Reilly Financial Advisors sold out of Sophiris Bio, Inc. (SPHS) in Q4 2015, closing a stake of 28 shares.

Reilly Financial Advisors first reported a position in SPHS in Q1 2015 and held it in 3 quarters. The position peaked at $0 in Q3 2015. 20 funds tracked by Wall St. Rank hold SPHS as of Q4 2015.

  • Reilly Financial Advisors reported no remaining Sophiris Bio, Inc. position as of Q4 2015 after selling out during the quarter.
  • Reilly Financial Advisors sold 28 Sophiris Bio, Inc. shares in Q4 2015.
  • Reilly Financial Advisors first reported a position in Sophiris Bio, Inc. in Q1 2015 and held it in 3 quarters.
  • Reilly Financial Advisors's Sophiris Bio, Inc. position peaked at $0 in Q3 2015.
  • 20 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q4 2015.

Based on Reilly Financial Advisors's 13F filing for Q4 2015, filed 22 Jan 2016.